| AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease R Krüger, W Kuhn, T Müller, D Woitalla, M Graeber, S Kösel, H Przuntek, ... Nature genetics 18 (2), 106-108, 1998 | 1795 | 1998 |
| Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients D Blum-Degena, T Müller, W Kuhn, M Gerlach, H Przuntek, P Riederer Neuroscience letters 202 (1-2), 17-20, 1995 | 1037 | 1995 |
| Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease KM Strauss, LM Martins, H Plun-Favreau, FP Marx, S Kautzmann, D Berg, ... Human molecular genetics 14 (15), 2099-2111, 2005 | 758 | 2005 |
| Increased susceptibility to sporadic Parkinson's disease by a certain combined α‐synuclein/apolipoprotein E genotype R Krüger, AM Menezes Vieira‐Saecker, W Kuhn, D Berg, T Müller, ... Annals of Neurology: Official Journal of the American Neurological …, 1999 | 338 | 1999 |
| Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double‐blind placebo‐controlled trial CG Goetz, P Damier, C Hicking, E Laska, T Müller, CW Olanow, O Rascol, ... Movement disorders: official journal of the Movement Disorder Society 22 (2 …, 2007 | 302 | 2007 |
| Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease T Müller, T Büttner, AF Gholipour, W Kuhn Neuroscience letters 341 (3), 201-204, 2003 | 297 | 2003 |
| Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease A Storch, WH Jost, P Vieregge, J Spiegel, W Greulich, J Durner, T Müller, ... Archives of neurology 64 (7), 938-944, 2007 | 280 | 2007 |
| Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and … WH Poewe, G Deuschl, A Gordin, ER Kultalahti, M Leinonen, ... Acta neurologica scandinavica 105 (4), 245-255, 2002 | 266 | 2002 |
| Short communication Interleukin‐6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease T Müller, D Blum‐Degen, H Przuntek, W Kuhn Acta Neurologica Scandinavica 98 (2), 142-144, 1998 | 243 | 1998 |
| Catechol-O-methyltransferase inhibitors in Parkinson’s disease T Müller Drugs 75 (2), 157-174, 2015 | 225 | 2015 |
| Elevated Plasma Levels of Homocysteine inParkinson’s Disease W Kuhn, R Roebroek, H Blom, D Van Oppenraaij, H Przuntek, ... European neurology 40 (4), 225-227, 1998 | 223 | 1998 |
| Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study) CW Olanow, P Damier, CG Goetz, T Mueller, J Nutt, O Rascol, ... Clinical neuropharmacology 27 (2), 58-62, 2004 | 209 | 2004 |
| Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers R Kruger, W Kuhn, KL Leenders, R Sprengelmeyer, T Muller, D Woitalla, ... Neurology 56 (10), 1355-1362, 2001 | 193 | 2001 |
| Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients P Wintermeyer, R Krüger, W Kuhn, T Müller, D Woitalla, D Berg, G Becker, ... Neuroreport 11 (10), 2079-2082, 2000 | 189 | 2000 |
| Novel homozygous p. E64D mutation in DJ1 in early onset Parkinson disease (PARK7) R Hering, KM Strauss, X Tao, A Bauer, D Woitalla, EM Mietz, S Petrovic, ... Human mutation 24 (4), 321-329, 2004 | 186 | 2004 |
| Nigral endothelial dysfunction, homocysteine, and Parkinson's disease T Muller, B Weme, B Fowler, W Kuhn The Lancet 354 (9173), 126-127, 1999 | 177 | 1999 |
| Predictors of gastric emptying in Parkinson's disease O Goetze, AB Nikodem, J Wiezcorek, M Banasch, H Przuntek, T Mueller, ... Neurogastroenterology & Motility 18 (5), 369-375, 2006 | 172 | 2006 |
| Diagnostic staging of Parkinson’s disease: conceptual aspects H Przuntek, T Müller, P Riederer Journal of neural transmission 111, 201-216, 2004 | 165 | 2004 |
| Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients T Müller, C Erdmann, D Bremen, WE Schmidt, S Muhlack, D Woitalla, ... Clinical neuropharmacology 29 (2), 61-67, 2006 | 149 | 2006 |
| Drug therapy in patients with Parkinson’s disease T Müller Translational neurodegeneration 1, 1-13, 2012 | 144 | 2012 |
